Mineralocorticoid receptors: An appealing target to treat coronary microvascular dysfunction in diabetes

Diabetes

Volumn 64, Issue 1, 2015, Pages 3-5

  Bender, Shawn B ^a,b,c   Jia, Guanghong ^a,d   Sowers, James R ^a,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPLERENONE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

CARDIOVASCULAR MORTALITY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIABETIC PATIENT; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; NOTE; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; FEMALE; MALE; MICROCIRCULATION;

CORONARY CIRCULATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MICROCIRCULATION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84920024282     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1425     Document Type: Note

References (19)

1. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858-1868
2. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptormediated vascular insulin resistance: An early contributor to diabetes-related vascular disease? Diabetes 2013;62:313-319
3. Schäfer N, Lohmann C, Winnik S, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J 2013;34:3515-3524
4. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J 2012;33:191-202
5. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012;350:266-272
6. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
7. Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
8. Jeon JH, Kim KY, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008;22:1502-1511
9. Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: Implications in diabetes mellitus-Associated obesity and vascular dysfunction. Hypertension 2012;59:1069-1078
10. Garg R, Rao AD, Baimas-George M, et al. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015;64:2362242
11. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92:2552-2558
12. Kawata T, Daimon M, Hasegawa R, et al. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. Am Heart J 2006;151:798.e92e15
13. Kjaer A, Kristoffersen US, Tarnow L, Parving H-H, Hesse B. Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. Diabetes Res Clin Pract 2009;84:34-38
14. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96:643-650
15. Bavry AA, Handberg EM, Huo T, et al. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Am Heart J 2014;167:826-832
16. Mueller KB, Lu Q, Mohammad NN, et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology. 22 July 2014 [Epub ahead of print]
17. Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab 2014;16:268-272
18. Hwang MH, Yoo JK, Luttrell M, et al. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) 2013;125:513-520
19. Tomanek RJ. Formation of the coronary vasculature during development. Angiogenesis 2005;8:273-284